How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Consumer Goods and Retail · Forecast 2027–2033
Calming Pheromone Spray Market
- By Animal Type: Dogs, Cats, Horses, Small Pets (Rabbits, Guinea Pigs), Birds
- By Formulation Type: Aerosol Spray, Pump Spray, Diffuser Refill Spray, Travel Size Spray
- By Application Purpose: Anxiety Reduction, Aggression Control, Travel Stress Relief, Noise Phobia Management, Separation Anxiety
- By Distribution Channel: Veterinary Clinics, Pet Specialty Stores, Online Retail, Mass Retailers, Pharmacies
- By Active Ingredient Source: Synthetic Pheromones, Natural Extracts, Combination Formulations
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Dogs leads By Animal Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 298 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.181 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.189 →
Full report · locked preview
Everything inside the Calming Pheromone Spray Market report
A complete, evidence-based study - 12 chapters and 125 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Animal Type 5
Formulation Type 4
Application Purpose 5
Distribution Channel 5
Active Ingredient Source 3
Companies profiled
Ceva Santé Animale
Bayer Animal Health
Virbac
Zoetis
Elanco Animal Health
PetSafe (Radio Systems Corporation)
Adaptil (part of Ceva)
Feliway (part of Ceva)
Petsafe
Vetnique Labs
PetAg
Kingdom Pet Group
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Ceva Santé Animale
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Bayer Animal Health
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Virbac
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Zoetis
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Elanco Animal Health
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →PetSafe (Radio Systems Corporation)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Adaptil (part of Ceva)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Feliway (part of Ceva)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Petsafe
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Vetnique Labs
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →PetAg
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Kingdom Pet Group
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Pet Remedy
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Comfort Zone (part of PetSafe)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Sentry Pet Care
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,606M by 2033 · 7.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Dogs43.3
- Cats17.4
- Horses10.2
- Small Pets (Rabbits, Guinea Pigs)12.6
- Birds16.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$477.2M → $773.3M · 6.2%
Europe$332.6M → $641.9M · 8.6%
Asia Pacific$303.7M → $498.6M · 6.4%
Latin America$188.0M → $325.6M · 7.1%
Middle East and Africa$144.6M → $292.6M · 9.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.592026
7.612027
7.622028
7.632029
7.642030
7.662031
7.672032
7.682033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Ceva Santé Animale15.2
- Bayer Animal Health20.4
- Virbac8.1
- Zoetis11.8
- Elanco Animal Health8.7
- PetSafe (Radio Systems Corporation)7.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Animal Type21.6%
Formulation Type29.1%
Application Purpose10.5%
Distribution Channel23.8%
Active Ingredient Source15.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.5
- Europe25.4
- Asia Pacific19.7
- Latin America12.9
- Middle East and Africa11.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Ceva Santé Animale | 91 | 82 | 94 | 85 | 85 | 98 | 89 |
| Bayer Animal Health | 78 | 73 | 81 | 75 | 80 | 85 | 79 |
| Virbac | 73 | 74 | 65 | 80 | 76 | 66 | 72 |
| Zoetis | 71 | 59 | 82 | 77 | 62 | 72 | 71 |
| Elanco Animal Health | 64 | 63 | 63 | 56 | 76 | 58 | 63 |
| PetSafe (Radio Systems Corporation) | 65 | 50 | 71 | 63 | 59 | 50 | 60 |
| Adaptil (part of Ceva) | 51 | 51 | 50 | 46 | 62 | 60 | 53 |
| Feliway (part of Ceva) | 54 | 60 | 51 | 40 | 53 | 50 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Ceva Santé Animale
- Bayer Animal Health
- Virbac
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Ceva Santé Animale | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Bayer Animal Health | ◐ | ◐ | ✓ | ◐ | ✓ | ✓ |
| Virbac | ✓ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Zoetis | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Elanco Animal Health | ✓ | ◐ | ◐ | − | ✓ | − |
| PetSafe (Radio Systems Corporation) | ◐ | ◐ | ◐ | ◐ | − | − |
| Adaptil (part of Ceva) | ◐ | − | ◐ | − | ◐ | − |
| Feliway (part of Ceva) | ◐ | ◐ | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Ceva Santé Animale89
2Bayer Animal Health79
3Virbac72
4Zoetis71
5Elanco Animal Health63
6PetSafe (Radio Systems Corporation)60
7Adaptil (part of Ceva)53
8Feliway (part of Ceva)51
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Ceva Santé AnimaleBayer Animal Health
Challenger2
Strong scale, closing on the leaders.
VirbacZoetis
Contender2
Focused players with pockets of strength.
Elanco Animal HealthPetSafe (Radio Systems Corporation)
Niche2
Specialists in a single segment or region.
Adaptil (part of Ceva)Feliway (part of Ceva)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Animal Type in North America, then scale across Calming Pheromone Spray Market — a $154M beachhead inside a $2.31B market.
Beachhead (SOM)$154Mobtainable near-term
Serviceable (SAM)$910Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Dogs
Best fit — highest urgency & budget in Animal Type.
Economic buyer79 fit
Cats
Strong fit — clear ROI and a fast path to value.
End user66 fit
Horses
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Animal Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Formulation Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application Purpose
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel29%
Digital / self-serve18%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Animal Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Calming Pheromone Spray Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified21%
Evaluation12%
Closed-won6%
$21.3KCAC
$85KLTV
4.0:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Calming Pheromone Spray Market is a resilient opportunity — $5.33B by 2033, compounding at 3.2%.
TAM · 2025$4.14Btoday
TAM · 2033$5.33Bforecast
CAGR3.2%2027–2033
Cumulative$42.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.33BTotal addressable market
SAM$1.92BServiceable available market
SOM$362MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.2% CAGR
Demand compounds through 2033, outpacing GDP across Animal Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Animal Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.33BLarge & growingTAM by 2033 at 3.2% CAGR
$1.92BServiceable nowreachable with today’s model
$362MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.16BBear2.1% CAGR
$5.33BBase3.2% CAGR
$6.82BBull4.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Formulation Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Calming Pheromone Spray Market — a $9.98B market by 2033. Plan: grow share from 10.1% to 17.9%.
Market size · 2033$9.98Btotal addressable
Market CAGR8.1%2027–2033
Target share17.9%from 10.1% today
Revenue ambition$1.79Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.1% | 17.9% | Ahead |
| Revenue | $915M | $1.79B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 30.7% | 45.2% | On track |
| Customer retention | 87.9% | 95.5% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Animal Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Formulation Type capability
A defensible second engine — invest in Formulation Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Animal Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Formulation Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $180M capacity & capability investment
- Greenlight bolt-on M&A in Formulation Type
- Authorise North America expansion plan
- Fund R&D program for Animal Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Calming Pheromone Spray Market conversation — a $3.00B market you can size, segment and defend in minutes.
Market size · 2033$3.00Btotal opportunity
Growth3.4%CAGR to 2033
Addressable buyers950+accounts in scope
Typical ROI6.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Animal Type
Goal Grow share in Animal Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.3×return on cost, year one
< 3 mopayback period
$46K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Ceva Santé AnimaleBayer Animal HealthVirbacZoetisElanco Animal HealthPetSafe (Radio Systems Corporation)Adaptil (part of Ceva)Feliway (part of Ceva)+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Calming Pheromone Spray Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Calming Pheromone Spray Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Consumer Goods and Retail · scroll →Calming Pheromone Diffuser Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportCalming Chews for Dogs Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportCalming Aids for Dogs Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportSoft Drink Dispensers Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportCalligraphy Pen Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportHome Gym Exercise Equipment Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportRetail Shelving Systems Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportCalf Sleeve Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportCommercial Frozen Beverage Machines Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportSmart Garage Door Controllers Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportCalendula Water Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportCalendula Face Cream Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.